Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Jan. 6, 2015, 67 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $228.16 to $2,641,920.00.

Highlighted Stocks Traded by Insiders:

Enanta Pharmaceuticals (ENTA) - FREE Research Report

Luly Jay R., who is President and CEO at Enanta Pharmaceuticals, sold 15,000 shares at $50.43 on Jan. 6, 2015. Following this transaction, the President and CEO owned 506,393 shares meaning that the stake was reduced by 2.88% with the 15,000-share transaction.

The shares most recently traded at $49.81, down $0.62, or 1.25% since the insider transaction. Historical insider transactions for Enanta Pharmaceuticals go as follows:

  • 4-Week # shares bought: 1,000
  • 4-Week # shares sold: 15,000
  • 12-Week # shares bought: 1,000
  • 12-Week # shares sold: 40,000
  • 24-Week # shares bought: 1,000
  • 24-Week # shares sold: 65,000

The average volume for Enanta Pharmaceuticals has been 381,000 shares per day over the past 30 days. Enanta Pharmaceuticals has a market cap of $928.7 million and is part of the health care sector and drugs industry. Shares are down 3.87% year-to-date as of the close of trading on Tuesday.

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the infectious disease field in the United States. The company has a P/E ratio of 27.7. Currently, there are 3 analysts who rate Enanta Pharmaceuticals a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ENTA - FREE

TheStreet Quant Ratings rates Enanta Pharmaceuticals as a hold. The company's strengths can be seen in multiple areas, such as its notable return on equity, robust revenue growth and largely solid financial position with reasonable debt levels by most measures. However, as a counter to these strengths, we also find weaknesses including unimpressive growth in net income and weak operating cash flow. Get the full Enanta Pharmaceuticals Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

HSN (HSNI) - FREE Research Report

Brand William C, who is Chief Marketing Officer at HSN, sold 3,000 shares at $75.60 on Jan. 6, 2015. Following this transaction, the Chief Marketing Officer owned 34,996 shares meaning that the stake was reduced by 7.9% with the 3,000-share transaction.

The shares most recently traded at $73.82, down $1.78, or 2.41% since the insider transaction. Historical insider transactions for HSN go as follows:

  • 4-Week # shares sold: 12,763
  • 12-Week # shares sold: 12,763
  • 24-Week # shares sold: 22,763

The average volume for HSN has been 306,400 shares per day over the past 30 days. HSN has a market cap of $3.9 billion and is part of the services sector and specialty retail industry. Shares are down 2.93% year-to-date as of the close of trading on Tuesday.

HSN, Inc. operates as an interactive multi-channel retailer in the United States. It operates through two segments, HSN and Cornerstone. The stock currently has a dividend yield of 1.89%. The company has a P/E ratio of 24.1. Currently, there are 5 analysts who rate HSN a buy, no analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on HSNI - FREE

TheStreet Quant Ratings rates HSN as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, reasonable valuation levels, solid stock price performance, expanding profit margins and notable return on equity. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full HSN Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Martin Midstream Partners (MMLP) - FREE Research Report

Bondurant Robert D, who is Executive VP and CFO at Martin Midstream Partners, bought 211 shares at $26.88 on Jan. 6, 2015. Following this transaction, the Executive VP and CFO owned 21,846 shares meaning that the stake was boosted by 0.98% with the 211-share transaction.

Tauscher Randall, who is Executive Vice President/COO at Martin Midstream Partners, bought 84 shares at $26.88 on Jan. 6, 2015. Following this transaction, the Executive Vice President/COO owned 13,444 shares meaning that the stake was boosted by 0.63% with the 84-share transaction.

The shares most recently traded at $27.41, up $0.53, or 1.93% since the insider transaction. Historical insider transactions for Martin Midstream Partners go as follows:

  • 4-Week # shares bought: 623
  • 4-Week # shares sold: 600
  • 12-Week # shares bought: 623
  • 12-Week # shares sold: 600
  • 24-Week # shares bought: 12,519
  • 24-Week # shares sold: 600

The average volume for Martin Midstream Partners has been 278,900 shares per day over the past 30 days. Martin Midstream Partners has a market cap of $1.0 billion and is part of the basic materials sector and energy industry. Shares are up 1.45% year-to-date as of the close of trading on Tuesday.

Martin Midstream Partners L.P. collects, transports, stores, and markets petroleum products and by-products in the United States Gulf Coast region. The stock currently has a dividend yield of 11.4%. Currently, there are 3 analysts who rate Martin Midstream Partners a buy, no analysts rate it a sell, and 4 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on MMLP - FREE

TheStreet Quant Ratings rates Martin Midstream Partners as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, generally higher debt management risk and disappointing return on equity. Get the full Martin Midstream Partners Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null